熱門資訊> 正文
Vor Bio宣布1.5亿美元私募
2025-12-15 21:45
- Vor Bio (NASDAQ:VOR) announced on Monday that it has entered into a securities purchase agreement to sell 13.87M shares of its common stock at a price of $10.81 per share in a private placement.
- The company expects the gross proceeds to be approximately $150M and is expected to close on or about December 18, 2025.
- The institutional investors, like RA Capital Management, Forbion, Frazier Life Sciences, Caligan Partners, Logos Capital, and Venrock Healthcare Capital Partners, are participating in the financing, and Forbion is being granted the right to appoint one director to the company’s board of directors.
- The company plans to use the net proceeds for advancement of the clinical development of telitacicept, including the ongoing global Phase 3 clinical trial for myasthenia gravis and Sjögren's disease, and for working capital and general corporate purposes.
- Shares +3.13%.
More on Vor Biopharma
- Vor Biopharma: J.P. Morgan Makes Bull Case After Corporate Actions Slam Stock Price
- Vor Biopharma: Transformed Company Is A High Risk Buy On Autoimmune Disease Promise
- Vor Bio spikes as J.P. Morgan starts at Overweight on lead asset
- Vor Biopharma slumps 26%, prices $100M equity at $10 per share
- Seeking Alpha’s Quant Rating on Vor Biopharma
推薦文章
華盛早報 | 特朗普再發驚人言論！美元跌至四年低谷，金價續創新高；聯合健康績后重挫近20%
1月28日外盤頭條：美元跌至四年低點 特朗普稱不擔心 谷歌推出低價版AI Plus 特朗普關税落地概率不足三成
美股機會日報 | 美光擬豪擲240億美元擴產存儲芯片！聯合健康遭雙重利空打擊，盤前暴跌15%
再出手飆漲超60%！特朗普政府重金入股美稀土公司，這份「關鍵礦產公司名單」請收好
華盛早報 | 特朗普突發貿易威脅！對韓國加税至25%；白銀「深V」閃崩后又急升
新股申購 | 國恩科技今起招股！一手入場費8484.71港元
特朗普政府16億美元入股美國稀土公司，佈局稀土供應鏈
摩根士丹利和美銀看好新興市場套利交易 去年回報已創2009年以來最強
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
